What is Synapse Biomedical?
Synapse Biomedical operates at the intersection of neurology and respiratory care, specializing in the research, development, and commercialization of advanced neurostimulation products. The company is best known for its NeuRx Diaphragm Pacing System, a breakthrough technology engineered to mitigate Ventilator Induced Diaphragm Dysfunction (VIDD). By providing a minimally invasive alternative to traditional mechanical ventilation, Synapse Biomedical serves a vital role for patients suffering from spinal cord injuries and ALS. With a proven track record of treating over 2,000 patients, the organization has established itself as a leader in enhancing patient independence and reducing long-term healthcare reliance.
How much funding has Synapse Biomedical raised?
Synapse Biomedical has raised a total of $910K across 2 funding rounds:
Debt
$350K
Debt
$560K
Debt (2020): $350K with participation from PPP
Debt (2021): $560K led by PPP
Key Investors in Synapse Biomedical
PPP
Public-Private Partnership
What's next for Synapse Biomedical?
With the recent influx of capital, Synapse Biomedical is well-positioned to scale its commercial operations and expand the clinical reach of its diaphragm pacing technology. The company's strategic roadmap likely involves deepening its penetration into hospital systems and investing in further clinical research to broaden the indications for its neurostimulation suite. As the firm transitions into a more mature enterprise phase, the focus will remain on optimizing patient outcomes and streamlining the adoption of its minimally invasive procedures within the global healthcare infrastructure.
See full Synapse Biomedical company page
